ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2099

Lesser Impact of Lower-Small Joint Involvement on Pain Than Upper-Small Joint in Rheumatoid Arthritis: Analysis Based on a Large Rheumatoid Arthritis Database in Japan

Tetsuji Sawada1, Susumu Nishiyama2, Shigemoto Igari1, Toshihiro Matsui3 and Shigeto Tohma4, 1Tokyo Medical University Hospital, Shinjuku Tokyo, Japan, 2Kurashiki Medical Center, Kurashiki, Japan, 3NHO Sagamihara National Hospital, Kanagawa, Japan, 4NHO Tokyo National Hospital, Dallas, TX

Meeting: ACR Convergence 2023

Keywords: Epidemiology, foot, pain, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Previous studies have highlighted the influence of pain, functional impairment, and affected joint distribution on the discordance in the global assessment of disease activity between patients with rheumatoid arthritis (RA) and their physicians. This study aimed to analyze the effect of affected joint distribution on pain in patients with RA, based on a nationwide RA database in Japan (NinJa).

Methods: The affected joints were divided into four regions: upper-large (shoulder, sternoclavicular, elbow, and wrist), upper-small (proximal interphalangeal and metacarpophalangeal), lower-large (hip, knee, ankle, and tarsometatarsal), and lower-small (metatarsophalangeal) joints. The modified joint index (JI) was calculated using the following formula: number of tender joint counts (instead of the sum of tender and swollen joint counts in the original JI [Rheumatol Int 32:2569, 2012]) divided by the number of evaluable joints within each region. Multiple regression analysis was performed using the pain visual analog scale (VAS) as an objective variable and modified Health Assessment Questionnaire (mHAQ), CRP, and affected joint variables, including JIs and tender joint counts, as explanatory variables.

Results: Multiple regression analysis involving 13,653 RA patients revealed that mHAQ, upper-large joints, lower-large joints, CRP, and upper-small joints significantly contributed to pain VAS in the order of standardized partial regression coefficients (SPRCs), although the contribution of lower-small joints was insignificant (Figure 1). Further analysis using tender joint counts showed the impact of each affected joint on pain VAS in the following order of SPRCs: wrists, knees, ankles, shoulders, proximal interphalangeal (PIP) joints, elbows, metacarpophalangeal (MCP) joints, distal interphalangeal (DIP) joints, and hips (Figure 2). Notably, the effects of metatarsophalangeal (MTP) and toe interphalangeal (IP) joints, which were excluded from the disease activity score-28 (DAS28), were not statistically significant.

Conclusion: The effect of lower-small joint involvement on pain in RA is smaller than that of upper-small joint involvement. Thus, patients with RA are relatively less aware of MTP and toe IP joint pain as compared to PIP and MCP joints, and may not complain to their physicians, which could lead to forefoot joint deformities. Therefore, it is necessary to consider lower-small joint involvement, which is not included in DAS28 evaluation, and pay attention to its potential impact on management in RA patients.

Supporting image 1

Figure 1 Impact of affected joint distribution on pain visual analog scale in patients with rheumatoid arthritis. *Lower-small joint involvement is not statistically significant. mHAQ: modified Health Assessment Questionnaire; CRP: C-reactive protein.

Supporting image 2

Figure 2 Impact of affected joint on pain visual analog scale in patients with rheumatoid arthritis. *Lower-small joint involvement is not statistically significant. mHAQ: modified Health Assessment Questionnaire; CRP: C-reactive protein.


Disclosures: T. Sawada: AbbVie/Abbott, 5, 6, Asahikasei, 5, 6, AstraZeneca, 6, Chugai, 5, 6, Eisai, 6, Eli-Lily, 6, Jansen, 6, Mitsubishi-Tanabe, 6, Ono Pharmaceutical, 6, Pfizer, 6, Taisho, 6, UCB, 6, Viatris, 6; S. Nishiyama: AbbVie/Abbott, 6, Asahi Kasei Pharma Corporation, 1, AstraZeneca, 6, AYUMI Pharmaceutical Corporation, 12, Financial support for the OKAYAMA medical conference., Chugai Pharma Manufacturing Co., Ltd., 6, Eisai Co., Ltd., 6, GlaxoSmithKlein(GSK), 1, 6, Kissei PharmaceuticalCo., Ltd., 6, Santen Pharmaceutical Co., Ltd., 6, Taisho Pharmaceutical Co., Ltd., 6; S. Igari: None; T. Matsui: Abbie, 6, Asahikasei Pharma Corp., 5, 6, Astellas, 6, Chugai Pharmaceutical Co, Ltd., 5, 6, Eisai Co., Ltd., 6, Eli Lilly Japan, 6, Ono Pharmaceutical Co., Ltd.,, 6, Pfizer Japan Inc., 6; S. Tohma: AbbVie/Abbott, 5, AsahiKASEI Co., Ltd., 6, Chudai Pharmaceutical Co., Ltd., 5, Mitsubishi Tanabe Pharma Corporation, 5, Pfizer Japan Inc., 6.

To cite this abstract in AMA style:

Sawada T, Nishiyama S, Igari S, Matsui T, Tohma S. Lesser Impact of Lower-Small Joint Involvement on Pain Than Upper-Small Joint in Rheumatoid Arthritis: Analysis Based on a Large Rheumatoid Arthritis Database in Japan [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/lesser-impact-of-lower-small-joint-involvement-on-pain-than-upper-small-joint-in-rheumatoid-arthritis-analysis-based-on-a-large-rheumatoid-arthritis-database-in-japan/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lesser-impact-of-lower-small-joint-involvement-on-pain-than-upper-small-joint-in-rheumatoid-arthritis-analysis-based-on-a-large-rheumatoid-arthritis-database-in-japan/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology